- Home
- RFIL vs CGTX Comparison
RFIL vs CGTX Comparison
Compare RFIL & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RFIL | CGTX |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.5M | 94.5M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RFIL | CGTX |
|---|---|---|
| Price | $11.30 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $9.25 | $3.33 |
| AVG Volume (30 Days) | 143.6K | ★ 771.8K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $55,325,000.00 | N/A |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $1,135.00 | ★ N/A |
| Revenue Growth | ★ 10.22 | N/A |
| 52 Week Low | $3.39 | $0.22 |
| 52 Week High | $12.24 | $3.83 |
Technical Indicators
Market Signals| Indicator | RFIL | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 43.68 |
| Support Level | $6.11 | $0.98 |
| Resistance Level | $12.07 | $1.21 |
| Average True Range (ATR) | 0.87 | 0.08 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 76.64 | 37.50 |
Price Performance
Historical ComparisonAbout RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.